Last reviewed · How we verify
Clobazam Medium Dose
Clobazam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to reduce seizure activity.
Clobazam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to reduce seizure activity. Used for Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Adjunctive treatment of focal seizures.
At a glance
| Generic name | Clobazam Medium Dose |
|---|---|
| Also known as | Onfi™ |
| Sponsor | Lundbeck LLC |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Clobazam binds to GABA-A receptors on neurons, potentiating the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx and neuronal hyperpolarization, raising the seizure threshold and reducing the frequency and severity of seizures. It is a 1,5-benzodiazepine with a different structure from classical 1,4-benzodiazepines, which may contribute to its favorable tolerability profile in epilepsy.
Approved indications
- Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
- Adjunctive treatment of focal seizures
Common side effects
- Somnolence
- Ataxia
- Fatigue
- Dizziness
- Irritability
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |